• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞生长因子/分散因子(HGF/SF)及其受体(cMET)的过表达与儿童及青年乳头状甲状腺癌患者的高转移和复发风险相关。

Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.

作者信息

Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle R M, Francis G L

机构信息

Department of Paediatrics, Walter Reed Army Medical Center, Washington, DC, USA.

出版信息

Clin Endocrinol (Oxf). 2000 Nov;53(5):635-44. doi: 10.1046/j.1365-2265.2000.01124.x.

DOI:10.1046/j.1365-2265.2000.01124.x
PMID:11106926
Abstract

OBJECTIVE

The study determined if hepatocyte growth factor/scatter factor (HGF/SF) or the HGF/SF receptor (cMET) might be important for metastasis in thyroid cancer.

DESIGN

We examined HGF/SF and cMET expression by immunohistochemistry in a retrospective group of benign and malignant thyroid lesions from children and young adults, and correlated the intensity of expression with clinical outcome.

PATIENTS

Patients included 42 children and young adults with papillary thyroid carcinomas (PTC), seven with follicular thyroid carcinomas (FTC), two with medullary thyroid carcinomas (MTC), 14 with benign thyroid disorders, and two with normal thyroids.

MEASUREMENTS

Expression of cMET was graded from 0 (absent) to 4 (intense); and HGF/SF expression was graded from 0 (absent-minimal) to 3 (diffuse and intense).

RESULTS

cMET staining was greater in PTC (mean intensity 2.3 +/- 0.4 vs. 0.8 +/- 0.2, P < 0.005) and FTC (2.4 +/- 0.6 vs. 0.8 +/- 0.2, P = 0.04) than benign lesions (0.8 +/- 0.2) or normal thyroids (0.4 +/- 0.5). PTC with intense cMET staining had shorter disease free survival (P = 0.05) and increased HGF/SF staining (r = 0.39, P = 0.017). HGF/SF correlated with the extent of disease at diagnosis (r = 0.33, P = 0.049). Patients with PTC were stratified into quartiles based on combined cMET and HGF/SF staining. Those with intense cMET and HGF/SF staining were younger (P = 0.05), and had reduced disease free survival (P = 0.03).

CONCLUSIONS

We conclude that increased cMET and HGF/SF expression is associated with a high risk for metastasis and recurrence in children and young adults with papillary thyroid carcinoma.

摘要

目的

本研究旨在确定肝细胞生长因子/分散因子(HGF/SF)或HGF/SF受体(cMET)对甲状腺癌转移是否重要。

设计

我们通过免疫组织化学检查了一组来自儿童和年轻成人的良性和恶性甲状腺病变的回顾性队列中的HGF/SF和cMET表达,并将表达强度与临床结果相关联。

患者

患者包括42例儿童和年轻成人的乳头状甲状腺癌(PTC)、7例滤泡状甲状腺癌(FTC)、2例髓样甲状腺癌(MTC)、14例良性甲状腺疾病患者以及2例甲状腺正常者。

测量

cMET表达从0(无)到4(强)分级;HGF/SF表达从0(无-极少)到3(弥漫且强)分级。

结果

PTC(平均强度2.3±0.4 vs. 0.8±0.2,P<0.005)和FTC(2.4±0.6 vs. 0.8±0.2,P = 0.04)中cMET染色比良性病变(0.8±0.2)或正常甲状腺(0.4±0.5)更明显。cMET染色强的PTC无病生存期较短(P = 0.05)且HGF/SF染色增加(r = 0.39,P = 0.017)。HGF/SF与诊断时疾病范围相关(r = 0.33,P = 0.049)。根据cMET和HGF/SF联合染色将PTC患者分层为四分位数。cMET和HGF/SF染色强的患者更年轻(P = 0.05),且无病生存期缩短(P = 0.03)。

结论

我们得出结论,cMET和HGF/SF表达增加与儿童和年轻成人乳头状甲状腺癌转移和复发的高风险相关。

相似文献

1
Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.肝细胞生长因子/分散因子(HGF/SF)及其受体(cMET)的过表达与儿童及青年乳头状甲状腺癌患者的高转移和复发风险相关。
Clin Endocrinol (Oxf). 2000 Nov;53(5):635-44. doi: 10.1046/j.1365-2265.2000.01124.x.
2
Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.肝细胞生长因子和c-met在正常甲状腺、非肿瘤性及肿瘤性结节中的表达
Thyroid. 1998 Feb;8(2):125-31. doi: 10.1089/thy.1998.8.125.
3
Tyrosine kinase expression is increased in papillary thyroid carcinoma of children and young adults.
Front Biosci. 2000 Mar 1;5:A1-9. doi: 10.2741/patel.
4
Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma.肝细胞生长因子(HGF)和c-MET的上调与甲状腺微小乳头状癌的亚临床中央淋巴结转移相关。
Ann Surg Oncol. 2014 Jul;21(7):2310-7. doi: 10.1245/s10434-014-3553-5. Epub 2014 Feb 22.
5
Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.Met/肝细胞生长因子受体的阴性/低表达可识别出具有远处转移高风险的甲状腺乳头状癌。
J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8. doi: 10.1210/jcem.82.7.4104.
6
Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas.肝细胞生长因子/分散因子(HGF/SF)及其受体cMET的共表达可预测脑膜瘤的复发。
Cancer Lett. 2004 Sep 15;213(1):117-24. doi: 10.1016/j.canlet.2004.04.026.
7
HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.HGF/C-MET 系统通路在甲状腺结节的良恶性组织学类型中的表达:免疫组织化学特征。
Histol Histopathol. 2012 Jan;27(1):113-21. doi: 10.14670/HH-27.113.
8
Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.信号转导与转录激活因子3(STAT3)在甲状腺乳头状癌及部分滤泡性腺瘤中的独特表达。
Histol Histopathol. 2003 Apr;18(2):393-9. doi: 10.14670/HH-18.393.
9
The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.血管内皮生长因子及血管内皮生长因子受体1的表达与儿童及年轻成人甲状腺乳头状癌的大小相关。
Thyroid. 2000 Apr;10(4):349-57. doi: 10.1089/thy.2000.10.349.
10
Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents.表达端粒酶的甲状腺癌在儿童和青少年中具有更具侵袭性的临床病程。
J Endocrinol Invest. 2002 Apr;25(4):302-8. doi: 10.1007/BF03344009.

引用本文的文献

1
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the .甲状腺髓样癌的分子基础与自然史:(几乎)都与……有关 。 (你提供的原文最后不完整,所以译文也只能到这个程度)
Cancers (Basel). 2023 Oct 5;15(19):4865. doi: 10.3390/cancers15194865.
2
The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.高危儿童实体瘤中的肝细胞生长因子/间充质上皮转化因子轴及靶向治疗药物的抗肿瘤活性。
Front Pediatr. 2022 Aug 10;10:910268. doi: 10.3389/fped.2022.910268. eCollection 2022.
3
Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline MET mutation - association or random chance?
一名携带种系MET突变的年轻患者,亚厘米大小的甲状腺乳头状癌发展为转移性低分化甲状腺癌——是关联还是随机巧合?
Thyroid Res. 2021 Aug 14;14(1):19. doi: 10.1186/s13044-021-00110-4.
4
Targeting c-Met on gastric cancer cells through a fully human fab antibody isolated from a large naive phage antibody library.通过从大型天然噬菌体抗体库中分离的全人源 Fab 抗体靶向胃癌细胞上的 c-Met。
Daru. 2020 Jun;28(1):221-235. doi: 10.1007/s40199-020-00334-z. Epub 2020 Mar 19.
5
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.放射性碘难治性甲状腺癌:再分化疗法、管理及新疗法的分子基础
Cancers (Basel). 2019 Sep 17;11(9):1382. doi: 10.3390/cancers11091382.
6
MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer.在间变性甲状腺癌模型中,MET的过表达和激活有利于侵袭性。
Oncotarget. 2019 Mar 19;10(23):2320-2334. doi: 10.18632/oncotarget.26798.
7
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.c-Met抑制剂的临床前和临床试验失败:评估通路活性作为一种有前景的选择标准。
Oncotarget. 2019 Jan 4;10(2):184-197. doi: 10.18632/oncotarget.26546.
8
Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond.晚期甲状腺癌的系统治疗导航:从标准治疗到个性化治疗及其他
J Endocr Soc. 2018 Aug 13;2(10):1109-1130. doi: 10.1210/js.2018-00180. eCollection 2018 Oct 1.
9
MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.miR-34a:肾细胞癌标志性特征的关键调节因子。
Oxid Med Cell Longev. 2017;2017:3269379. doi: 10.1155/2017/3269379. Epub 2017 Sep 20.
10
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.甲状腺髓样癌:临床特征和针对酪氨酸激酶的治疗策略新见解。
Mol Diagn Ther. 2017 Dec;21(6):607-620. doi: 10.1007/s40291-017-0289-5.